Suven Life Sciences Ltd has received product patents from India and Japan for the new chemical entities (NCEs) used in the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2026 and 2032 in India and Japan respectively.
The granted claims of the patents are from the mechanism of action include the class of selective 5-HT6 compounds and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
